An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Mirogabalin (Primary)
- Indications Neuropathic pain
- Focus Registrational; Therapeutic Use
- Acronyms AMELA
- Sponsors Daiichi Sankyo Company
- 28 Apr 2023 Results from open label part, published in the Pain and Therapy
- 14 Dec 2022 Results published in the Neurology
- 28 Mar 2022 According to a Daiichi Sankyo Company media release, the company obtained approval in Japan to change the indication of the analgesic "Tarlige Tablets" (mirogabalin besilate) from "peripheral neuropathic pain" to "neuropathic pain."